Data presented at the ATTD conference demonstrates Tandem Diabetes Care's (TNDM) Control-IQ technology's ability to make a positive and sustained impact on diabetes care.

Tandem Diabetes is also on track to launch its second-generation AID system — t:slim X2 — with Control IQ in international markets in the latter half of 2020.

Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...

The Control-IQ artificial pancreas system also offers auto-bolusing to people with diabetes who use Tandem’s t:slim X2 insulin pump. If the algorithm predicts—or the connected CGM detects—an ...

Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology ...

Mobi pumps are also equipped with Tandem’s existing Control-IQ technology. The algorithm takes in blood sugar readings from a compatible continuous glucose monitor, then uses those data to ...

Tandem Diabetes Care, Inc. TNDM recently presented data on real-world use of the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology at the 14th International Conference ...

In January 2020, the company commercially launched the t:slim X2 insulin pump with Control-I technology in the United States. Tandem Diabetes is also on track to launch its second-generation AID ...

Tandem Diabetes Care, Inc. TNDM recently presented data on real-world use of the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology at the 14th International Conference on ...